Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 40
Filter
1.
Rev. AMRIGS ; 66(3): 01022105, jul.-set. 2022.
Article in Portuguese | LILACS | ID: biblio-1425027

ABSTRACT

Introdução: A Influenza é uma doença respiratória altamente contagiosa, prevenível por vacinação, afetando todos os grupos etários,com morbidade e mortalidade variáveis. O objetivo deste estudo foi analisar a relação da situação vacinal dos pacientes com Influenza A/B atendidos com Síndrome Respiratória Aguda Grave. Métodos: Estudo retrospectivo, a partir das notificações do Sistema de Informação de Agravos de Notificação Compulsório do Brasil, de pacientes com esquema vacinal conhecido para Influenza A/B em um hospital-escola do interior do Rio Grande do Sul (2012 a 2018). Resultados: Foram incluídos 596 casos de SRAG, sendo 179 (30,0%) por vírus respiratórios [92 (51,4%) Influenza A/B e 87 (48,6%) outros vírus respiratórios]. Na faixa etária de maiores de 50 anos, a frequência foi 28,2%, 6 meses a 1 ano foi de 19,6%, seguido de 13% no grupo etário de 2 a 4 anos. O esquema vacinal estava completo em 59,8% dos casos, sendo que em 37,5% dos pacientes apresentavam esquema vacinal incompleto. O tratamento antiviral foi administrado em 90,2% do pacientes com SRAG por Influenza A/B, e a alta hospitalar ocorreu em 91,3% dos casos. Conclusão: A vacinação é uma estratégia para prevenção de complicações relacionadas à Influenza. No entanto, a SRAG é uma apresentação com diagnóstico diferencial amplo, e as causas virais necessitam de confirmação para uma otimização da terapêutica antiviral. A equipe de saúde deve estar atenta a pacientes com riscos de SRAG, a fim de minimizar os desfechos negativos, mesmo nos vacinados.


Introduction: Influenza is a highly contagious respiratory disease, preventable by vaccination, affecting all age groups, with variable morbidity and mortality. The objective of this study was to analyze the relationship between the vaccination status of Influenza A/B patients seen with Severe Acute Respiratory Syndrome. Methods: Retrospective study, from notifications of the Brazilian Compulsory Notification Agencies Information System (Sistema de Informação de Agravos de Notificação Compulsório do Brasil), of patients with known vaccination schemes for Influenza A/B in a teaching hospital in the interior of Rio Grande do Sul (2012 to 2018). Results: Of the 596 cases of SARS included, 179 (30.0%) were due to respiratory viruses [92 (51.4%) Influenza A/B and 87 (48.6%) other respiratory viruses]. In the age group over 50 years, the frequency was 28.2%, from 6 months to 1 year old was 19.6%, followed by 13% in the age group of 2 to 4 years. The vaccination schedule was complete in 59.8% of cases, with 37.5% having an incomplete vaccination scheme. Antiviral treatment was administered in 90.2% of the patients with SARS by Influenza A/B, and hospital discharge occurred in 91.3% of the cases. Conclusion: Vaccination is a strategy to prevent complications related to Influenza. However, SARS is a presentation with wide differential diagnosis, and the viral causes need confirmation for an optimization of the antiviral therapy. The healthcare team must be aware of patients at risk of SARS to minimize negative outcomes, even in vaccinated patients.


Subject(s)
Respiratory Tract Diseases , Influenza, Human
2.
Acta méd. costarric ; 64(3)sept. 2022.
Article in Spanish | LILACS-Express | LILACS | ID: biblio-1447054

ABSTRACT

Objetivo: Perfilar las características de los pacientes y los factores que llevan a la prescripción de antibióticos, en todos los niños menores de 2 años previamente sanos internados con diagnóstico de bronquiolitis, durante un periodo de 12 meses en el hospital pediátrico especializado. Métodos: estudio observacional descriptivo de las características clínico-epidemiológicas de los niños previamente sanos menores de dos años hospitalizados con el diagnóstico de bronquiolitis, del 01 de enero al 31 de diciembre del año 2018 en el Hospital Nacional de Niños "Dr. Carlos Sáenz Herrera" de la Caja Costarricense de Seguro Social de Costa Rica, con un análisis comparativo entre los factores asociados con la utilización o no de antibióticos durante su hospitalización. Resultados: Se incluyó un total de 261 niños previamente sanos hospitalizados con bronquiolitis, con una edad promedio de 7.3 meses y predomino del sexo masculino (n=160, 61.3%). El 24.5% presentó exposición a fumado pasivo. Un 66.1% de los pacientes no tuvieron antecedente de sibilancias previas al internamiento y un 52.2% con el antecedente familiar de asma bronquial. Se registró que el 17.2% (n=45) recibió antibióticos durante su hospitalización. Los factores asociados con la prescripción de los antibióticos fueron la presencia de opacidades pulmonares (p=0.001, OR: 32.2) e infiltrados bronconeumónicos (p=0.002, OR:2.72) en la radiografía de tórax, la escalada a terapia con cánula de alto flujo (p<0.001, OR: 4.43) y la ventilación mecánica asistida (p=0.001, OR: 7.17). Conclusión: Los dos factores que llevan al médico a prescribir antibióticos al paciente sano con BQL son el deterioro del patrón respiratorio que lleva a la necesidad de intubar y ventilar y la presencia de opacidades pulmonares e infiltrados bronconeumónicos.


Aim: Identify the patient characteristics and the factors related to the prescription of antibiotics, in all previously healthy children under 2 years of age hospitalized with a diagnosis of bronchiolitis, during a period of 12 months in a pediatric hospital. Methods: descriptive observational study of the clinical-epidemiological characteristics of previously healthy children under two years of age hospitalized with a diagnosis of bronchiolitis, from January 1 to December 31, 2018 at the National Children's Hospital "Dr. Carlos Sáenz Herrera" of the Costa Rican Social Security, with a comparative analysis between the factors associated with the use or not of antibiotics during hospitalization. Results: A total of 261 previously healthy children hospitalized with bronchiolitis were included, with a mean age of 7.3 months and a predominance of males (n=160, 61.3%). 24.5% presented exposure to passive smoking. 66.1% of the patients had no history of wheezing prior to hospitalization and 52.2% had a family history of bronchial asthma. It was recorded that 17.2% (n=45) received antibiotics during their hospitalization. Factors associated with the prescription of antibiotics were the presence of pulmonary opacities (p=0.001, OR: 32.2) and bronchopneumonic infiltrates (p=0.002, OR: 2.72) on chest radiography, escalation to high-pressure cannula therapy flow (p<0.001, OR: 4.43) and assisted mechanical ventilation (p=0.001, OR: 7.17). Conclusion: two factors that lead the physician to prescribe antibiotics in the healthy patient with bronchiolitis, the deterioration of the respiratory pattern that lead to intubation and ventilate the healthy patient with BQL and the presence of radiologic pulmonary opacities and bronchopneumonic infiltrates.

3.
Braz. j. biol ; 82: e231134, 2022. tab, graf
Article in English | LILACS, VETINDEX | ID: biblio-1249257

ABSTRACT

Chronic obstructive pulmonary disease (COPD) was estimated to be the third cause of global mortality by 2020. Acute exacerbation COPD (AECOPD) is a sudden worsening of COPD symptoms and could be due to virus/bacterial infections and air pollution. Increased expression of inflammatory markers in patients with AECOPD is associated with viral infection. This study aimed to detect different viruses and analyze the expression of various inflammatory markers associated with AECOPD patients. Three hundred and forty-seven patients diagnosed with COPD according to GOLD criteria were included in this study. Swab samples and blood were collected for the detection of viruses by RT-PCR and expression of inflammatory markers, respectively. Of the swab samples, 113 (32.6%) of samples were positive for virus detection. Of these, HRV (39.8%) was the predominant virus detected followed by FluB (27.4%) and FluA (22.1%). The presence of HRV was significantly higher (p=0.044) among the other detected viruses. When compared to healthy controls the expression levels of TNF-α, IL-6 and IL-8 were significantly higher (p<0.05) in virus-positive patients. The IL-6 and IL-8 were the next predominantly expressed in markers among the samples. The higher expression rate of IL-8 was significantly (p<0.05) associated with patients having COPD GOLD III severity level and smoking history. Although HRV was the predominant virus detected the combined prevalence of Influenza A and B surpassing the rate of HRV. The high-level expression of well known inflammatory markers of AECOPD, TNF-α, IL-6 and IL-8 indicates a chronic severe illness. These markers play an important role and could be used as a marker for determining the severity of AECOPD.


Estima-se que a doença pulmonar obstrutiva crônica (DPOC) seja a terceira causa de mortalidade global em 2020. A exacerbação aguda DPOC (AECOPD) é um agravamento súbito dos sintomas da DPOC e pode ser devido a infecções por vírus/bactérias e poluição do ar. O aumento da expressão de marcadores inflamatórios em pacientes com AECOPD está associado à infecção viral. Este estudo teve como objetivo detectar diferentes vírus e analisar a expressão de vários marcadores inflamatórios associados a pacientes com AECOPD. Trezentos e quarenta e sete pacientes com diagnóstico de DPOC de acordo com os critérios GOLD foram incluídos neste estudo. Amostras de swab e sangue foram coletadas para detecção de vírus por RT-PCR e expressão de marcadores inflamatórios, respectivamente. Das amostras de esfregaço, 113 (32,6%) amostras foram positivas para detecção de vírus. Nestas, o HRV (39,8%) foi o vírus predominante detectado, seguido do FluB (27,4%) e do FluA (22,1%). A presença de VFC foi significativamente maior (p = 0,044) entre os demais vírus detectados. Quando comparados a controles saudáveis, os níveis de expressão de TNF-α, IL-6 e IL-8 foram significativamente maiores (p <0,05) em pacientes com vírus positivo. A IL-6 e a IL-8 foram as próximas predominantemente expressas em marcadores entre as amostras. A maior taxa de expressão de IL-8 foi significativamente (p <0,05) associada a pacientes com grau de gravidade GOLD III da DPOC e história de tabagismo. Embora o HRV tenha sido o vírus predominante, a prevalência combinada de Influenza A e B ultrapassou a taxa de HRV. O alto nível de expressão de marcadores inflamatórios bem conhecidos de AECOPD, TNF-α, IL-6 e IL-8 indica uma doença crônica grave. Esses marcadores desempenham um papel importante e podem ser usados como um marcador para determinar a gravidade da AECOPD.


Subject(s)
Humans , Viruses , Pulmonary Disease, Chronic Obstructive/diagnosis , China/epidemiology , Cytokines/genetics , Mongolia
4.
Braz. j. biol ; 82: 1-8, 2022. tab, graf
Article in English | LILACS, VETINDEX | ID: biblio-1468467

ABSTRACT

Chronic obstructive pulmonary disease (COPD) was estimated to be the third cause of global mortality by 2020. Acute exacerbation COPD (AECOPD) is a sudden worsening of COPD symptoms and could be due to virus/bacterial infections and air pollution. Increased expression of inflammatory markers in patients with AECOPD is associated with viral infection. This study aimed to detect different viruses and analyze the expression of various inflammatory markers associated with AECOPD patients. Three hundred and forty-seven patients diagnosed with COPD according to GOLD criteria were included in this study. Swab samples and blood were collected for the detection of viruses by RT-PCR and expression of inflammatory markers, respectively. Of the swab samples, 113 (32.6%) of samples were positive for virus detection. Of these, HRV (39.8%) was the predominant virus detected followed by FluB (27.4%) and FluA (22.1%). The presence of HRV was significantly higher (p=0.044) among the other detected viruses. When compared to healthy controls the expression levels of TNF-α, IL-6 and IL-8 were significantly higher (p<0.05) in virus-positive patients. The IL-6 and IL-8 were the next predominantly expressed in markers among the samples. The higher expression rate of IL-8 was significantly (p<0.05) associated with patients having COPD GOLD III severity level and smoking history. Although HRV was the predominant virus detected the combined prevalence of Influenza A and B surpassing the rate of HRV. The high-level expression of well known inflammatory markers of AECOPD, TNF-α, IL-6 and IL-8 indicates a chronic severe illness. These markers play an important role and could be used as a marker for determining the severity of AECOPD.


Estima-se que a doença pulmonar obstrutiva crônica (DPOC) seja a terceira causa de mortalidade global em 2020. A exacerbação aguda DPOC (AECOPD) é um agravamento súbito dos sintomas da DPOC e pode ser devido a infecções por vírus/bactérias e poluição do ar. O aumento da expressão de marcadores inflamatórios em pacientes com AECOPD está associado à infecção viral. Este estudo teve como objetivo detectar diferentes vírus e analisar a expressão de vários marcadores inflamatórios associados a pacientes com AECOPD. Trezentos e quarenta e sete pacientes com diagnóstico de DPOC de acordo com os critérios GOLD foram incluídos neste estudo. Amostras de swab e sangue foram coletadas para detecção de vírus por RT-PCR e expressão de marcadores inflamatórios, respectivamente. Das amostras de esfregaço, 113 (32,6%) amostras foram positivas para detecção de vírus. Nestas, o HRV (39,8%) foi o vírus predominante detectado, seguido do FluB (27,4%) e do FluA (22,1%). A presença de VFC foi significativamente maior (p = 0,044) entre os demais vírus detectados. Quando comparados a controles saudáveis, os níveis de expressão de TNF-α, IL-6 e IL-8 foram significativamente maiores (p <0,05) em pacientes com vírus positivo. A IL-6 e a IL-8 foram as próximas predominantemente expressas em marcadores entre as amostras. A maior taxa de expressão de IL-8 foi significativamente (p <0,05) associada a pacientes com grau de gravidade GOLD III da DPOC e história de tabagismo. Embora o HRV tenha sido o vírus predominante, a prevalência combinada de Influenza A e B ultrapassou a taxa de HRV. O alto nível de expressão de marcadores inflamatórios bem conhecidos de AECOPD, TNF-α, IL-6 e IL-8 indica uma doença crônica grave. Esses marcadores desempenham um papel importante e podem ser usados como um marcador para determinar a gravidade da AECOPD.


Subject(s)
Humans , Pulmonary Disease, Chronic Obstructive/microbiology , Pulmonary Disease, Chronic Obstructive/virology , Tumor Necrosis Factor-alpha/analysis , /analysis , /analysis
5.
Braz. j. biol ; 822022.
Article in English | LILACS-Express | LILACS, VETINDEX | ID: biblio-1468654

ABSTRACT

Abstract Chronic obstructive pulmonary disease (COPD) was estimated to be the third cause of global mortality by 2020. Acute exacerbation COPD (AECOPD) is a sudden worsening of COPD symptoms and could be due to virus/bacterial infections and air pollution. Increased expression of inflammatory markers in patients with AECOPD is associated with viral infection. This study aimed to detect different viruses and analyze the expression of various inflammatory markers associated with AECOPD patients. Three hundred and forty-seven patients diagnosed with COPD according to GOLD criteria were included in this study. Swab samples and blood were collected for the detection of viruses by RT-PCR and expression of inflammatory markers, respectively. Of the swab samples, 113 (32.6%) of samples were positive for virus detection. Of these, HRV (39.8%) was the predominant virus detected followed by FluB (27.4%) and FluA (22.1%). The presence of HRV was significantly higher (p=0.044) among the other detected viruses. When compared to healthy controls the expression levels of TNF-, IL-6 and IL-8 were significantly higher (p 0.05) in virus-positive patients. The IL-6 and IL-8 were the next predominantly expressed in markers among the samples. The higher expression rate of IL-8 was significantly (p 0.05) associated with patients having COPD GOLD III severity level and smoking history. Although HRV was the predominant virus detected the combined prevalence of Influenza A and B surpassing the rate of HRV. The high-level expression of well known inflammatory markers of AECOPD, TNF-, IL-6 and IL-8 indicates a chronic severe illness. These markers play an important role and could be used as a marker for determining the severity of AECOPD.


Resumo Estima-se que a doença pulmonar obstrutiva crônica (DPOC) seja a terceira causa de mortalidade global em 2020. A exacerbação aguda DPOC (AECOPD) é um agravamento súbito dos sintomas da DPOC e pode ser devido a infecções por vírus/bactérias e poluição do ar. O aumento da expressão de marcadores inflamatórios em pacientes com AECOPD está associado à infecção viral. Este estudo teve como objetivo detectar diferentes vírus e analisar a expressão de vários marcadores inflamatórios associados a pacientes com AECOPD. Trezentos e quarenta e sete pacientes com diagnóstico de DPOC de acordo com os critérios GOLD foram incluídos neste estudo. Amostras de swab e sangue foram coletadas para detecção de vírus por RT-PCR e expressão de marcadores inflamatórios, respectivamente. Das amostras de esfregaço, 113 (32,6%) amostras foram positivas para detecção de vírus. Nestas, o HRV (39,8%) foi o vírus predominante detectado, seguido do FluB (27,4%) e do FluA (22,1%). A presença de VFC foi significativamente maior (p = 0,044) entre os demais vírus detectados. Quando comparados a controles saudáveis, os níveis de expressão de TNF-, IL-6 e IL-8 foram significativamente maiores (p 0,05) em pacientes com vírus positivo. A IL-6 e a IL-8 foram as próximas predominantemente expressas em marcadores entre as amostras. A maior taxa de expressão de IL-8 foi significativamente (p 0,05) associada a pacientes com grau de gravidade GOLD III da DPOC e história de tabagismo. Embora o HRV tenha sido o vírus predominante, a prevalência combinada de Influenza A e B ultrapassou a taxa de HRV. O alto nível de expressão de marcadores inflamatórios bem conhecidos de AECOPD, TNF-, IL-6 e IL-8 indica uma doença crônica grave. Esses marcadores desempenham um papel importante e podem ser usados como um marcador para determinar a gravidade da AECOPD.

6.
Bol. méd. Hosp. Infant. Méx ; 78(3): 191-199, May.-Jun. 2021. tab, graf
Article in English | LILACS-Express | LILACS | ID: biblio-1285483

ABSTRACT

Abstract Background: Viral respiratory infections in pediatric patients with hematopoietic stem cell transplantation (HSCT) significantly impact morbidity and mortality. It is necessary to determine the viral agents and their frequency of presentation to understand their impact on transplantation patients’ evolution. Methods: From January 2017 to December 2019, we conducted a cross-sectional, descriptive, and observational study of patients who underwent HSCT with a viral respiratory infection. Viral identification was performed using multiplex polymerase chain reaction for nine respiratory viruses. Descriptive statistics were performed with a report of central tendency measures and percentages. Results: Of the 54 pediatric patients who underwent HSCT, 59.2% presented an airway infection; in turn, at least one viral agent was identified in 59.3% of these patients. The most frequent viral agents were influenza (25.9%), human rhinovirus (18.5%), and respiratory syncytial virus (18.5%). Viral co-infections occurred in 36.8% of the cases. The reported complications were supplemental oxygen requirement (73.6%), support with mechanical ventilation (21%), admission to the pediatric intensive care unit (15.7%), and mortality associated with a viral respiratory infection (10.5%). Conclusions: Viral respiratory infections are frequent in pediatric patients with HSCT; influenza A/B virus was the most frequent agent. As morbidity and mortality increase due to these infections in patients with HSCT, strategies are necessary for its prevention and timely treatment after transplantation.


Resumen Introducción: Las infecciones respiratorias virales en los pacientes pediátricos con trasplante de células progenitoras hematopoyéticas (TCPH) impactan significativamente la morbilidad y la mortalidad. Para comprender su impacto en la evolución de los pacientes receptores de trasplantes es necesario conocer la frecuencia de presentación y los agentes virales. Métodos: De enero de 2017 a diciembre de 2019 se llevó a cabo un estudio transversal, descriptivo y observacional de los pacientes sometidos a TCPH que tuvieron una infección viral de vías respiratorias. La identificación de los virus se realizó por medio de la prueba de reacción en cadena de la polimerasa multiplex para nueve virus respiratorios. Se realizó estadística descriptiva con reporte de medidas de tendencia central y porcentajes. Resultados: De los 54 pacientes incluidos, el 59.2% presentaron una infección de vías respiratorias y se identificó al menos un agente viral en el 59.3% de estos casos. Los virus más frecuentes fueron influenza (25.9%), rinovirus humano (18.5%) y virus sincitial respiratorio (18.5%). En el 36.8% de los casos se detectaron coinfecciones virales. Se presentaron las siguientes complicaciones: requerimiento de oxígeno suplementario (73.6%), soporte con ventilación mecánica (21%), ingreso a la unidad de cuidados intensivos pediátricos (15.7%) y muerte asociada a infección por virus respiratorios (10.5%). Conclusiones: Las infecciones respiratorias virales en los pacientes pediátricos con TCPH son frecuentes; el virus influenza A/B es el agente más habitual. Debido a que estas infecciones se asocian con mayor morbimortalidad en los pacientes con TCPH, son estrategias necesarias para su prevención y tratamiento oportuno posterior al trasplante.

7.
Medisan ; 25(2)mar.-abr. 2021. tab
Article in Spanish | LILACS, CUMED | ID: biblio-1250344

ABSTRACT

Introducción: Los virus constituyen las causas más frecuentes de infección respiratoria aguda, aunque el diagnóstico causal suele ser empírico dada la complejidad de su aislamiento. Objetivo: Caracterizar a pacientes menores de 5 años de edad con infecciones respiratorias agudas, según variables epidemiológicas, clínicas e imagenológicas. Métodos: Se efectuó una investigación descriptiva y transversal de 171 pacientes con infecciones respiratorias agudas y aislamiento viral mediante exudado nasofaríngeo profundo, egresados del Servicio de Neonatología del Hospital Docente Infantil Sur Antonio María Béguez César de Santiago de Cuba, desde el 2014 hasta el 2016, para lo cual se realizaron cálculos de frecuencias y porcentajes. Resultados: Predominaron los lactantes (57,9 %), el sexo masculino y los afectados con diagnósticos de neumonía (40,9 %) y bronquiolitis (28,0 %) por virus sincitial respiratorio y rinovirus. La supresión precoz de lactancia materna y tabaquismo fueron los factores de riesgo prevalentes. Tanto la fiebre como la tos y las secreciones nasales resultaron preponderantes, e infrecuentes las complicaciones. La consolidación alveolar prevaleció en pacientes con neumonía. Conclusiones: Se caracterizó epidemiológica y clínicamente a los pacientes con virus respiratorios y se evidenció discordancia con el predominio del patrón de infiltrado alveolar descrito en la bibliografía médica consultada.


Introduction: Viruses constitute the most frequent causes in acute respiratory infection, although the causal diagnosis is usually empiric given the complexity of its isolation. Objective: To characterize patients under 5 years with acute respiratory infections, according to epidemiological, clinical and imaging variables. Methods: A descriptive and cross-sectional investigation of 171 patients with acute respiratory infections and viral isolation was carried out by means of deep nasopharyngeal swab. They were discharged from the Neonatology Service of Antonio María Béguez César Southern Children Teaching Hospital in Santiago de Cuba, from 2014 to 2016, for which calculations of frequencies and percentages were carried out. Results: There was a prevalence of infants (57.9 %), the male sex and those affected patients with diagnosis of pneumonia (40.9 %) and bronchiolitis (28.0 %) due to respiratory syncytial virus and rhinovirus. The early suppression of breast feeding and nicotine addiction were the prevalent risk factors. Both fever and cough and the nasal secretions were preponderant, and the complications were infrequent. The alveolar consolidation prevailed in patients with pneumonia. Conclusions: Patients with respiratory virus were clinically and epidemiologically characterized and conflict with the pattern prevalence of alveolar infiltrates described in the consulted medical literature was evidenced.


Subject(s)
Respiratory Tract Infections/diagnosis , Respiratory Tract Infections/epidemiology , Respiratory Insufficiency , Secondary Care , Child, Preschool
8.
Rev. chil. infectol ; 38(2): 152-160, abr. 2021. ilus, tab, graf
Article in Spanish | LILACS | ID: biblio-1388225

ABSTRACT

INTRODUCCIÓN: La etiología de la enfermedad de Kawasaki (EK) es desconocida, planteándose que infecciones virales la gatillan en pacientes susceptibles. OBJETIVO: Estudiar la asociación temporal entre la circulación de virus respiratorios y hospitalizaciones por EK en la Región Metropolitana (RM), Chile, entre 2010-2017. METODOLOGÍA: Estudio ecológico retrospectivo de casos de EK en pacientes bajo 18 años de edad, en base a egresos hospitalarios. La circulación de virus se analizó mediante el reporte de la red de vigilancia metropolitana. Se utilizaron promedios móviles para EK (PMEK) y virus respiratorios (PMVR). RESULTADOS: Se registraron 14.902 casos de infecciones virales respiratorias entre 2010-2017. Se observó correlación directa entre PMVR-virus respiratorio sincicial (VRS) de un mes y año y PMEK del mes subsiguiente (coeficiente de correlación (ρ) = +0,441; p < 0,001), y una asociación similar para PMVR-influenza A (FLU A) (ρ = +0,362; p < 0,001). PMVR-influenza B (FLU B) y PMVR-metapneumovirus (MPV) presentan correlaciones directas con PMEK (ρ = +0,443; p < 0,001 y ρ = +0,412; p < 0,001, respectivamente), siendo contemporáneo en mes y año con EK para FLU B, mientras que MPV presenta un desfase de un mes entre PMVR y PMEK. CONCLUSIÓN: Existe correlación temporal directa entre la circulación de VRS, FLU A, FLU B y MPV con EK en niños de la RM, Chile.


BACKGROUND: The etiology of Kawasaki disease (KD) is unknown. It is believed that viral infections could trigger the disease in susceptible patients. AIM: To study the temporal association between the circulation of respiratory viruses and KD hospitalizations in the Metropolitan Region (MR), Chile, between 2010-2017. METHODS: Ecologic study consisting of a review of KD cases in children under 18 years of age based on hospital discharges. The circulation of respiratory viruses was analyzed using the report of the metropolitan surveillance network. Moving averages for KD (MAKD) and respiratory viruses (MARV) were used. RESULTS: 14,902 cases of respiratory virus infections were recorded between 2010-2017. A direct correlation was found between MARV-respiratory syncytial virus (RSV) of one month and year and MAKD of the subsequent month (correlation coefficient (ρ) = +0.441; p < 0.001). A similar association was found for MARV-influenza A (FLU A) (ρ = + 0.362; p < 0.001). MARV-influenza B (FLU B) and MARV-metapneumovirus (MPV) had direct correlations with MAKD (ρ = +0.443; p < 0.001 and ρ = +0.412; p < 0.001, respectively), being FLU B contemporary in month and year with KD, and MPV presenting a one-month lag. CONCLUSION: There is a direct temporal correlation between RSV, FLU A, FLU B and MPV circulation and KD in children from RM, Chile.


Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Child , Adolescent , Respiratory Tract Infections/epidemiology , Viruses , Respiratory Syncytial Virus Infections/epidemiology , Influenza, Human/epidemiology , Mucocutaneous Lymph Node Syndrome/epidemiology , Chile/epidemiology , Retrospective Studies , Respiratory Syncytial Virus, Human , Respiratory Syncytial Virus Infections/complications , Influenza, Human/complications , Hospitalization
9.
Rev. pediatr. electrón ; 18(1): 26-32, abr. 2021. tab
Article in Spanish | LILACS | ID: biblio-1369703

ABSTRACT

INTRODUCCIÓN. Las cardiopatías congénitas son un factor de riesgo para desarrollar enfermedad severa por virus respiratorio sincicial (VRS). En Chile no se conoce la hospitalización o letalidad por esta causa. El objetivo de este estudio fue determinar la letalidad de niños menores de 2 años con cardiopatías congénitas hospitalizados por infección por VRS en el hospital de niños Roberto del Río, Santiago, Chile. MÉTODO. Estudio descriptivo retrospectivo de revisión de fichas clínicas de niños menores de 24 meses con cardiopatía congénita, hospitalizados por infección respiratoria baja por VRS. Se registró edad, género, tipo de cardiopatía congénita, comorbilidades, días de hospitalización, ingreso a unidad de paciente crítico y letalidad en Hospital Roberto del Río durante los años 2014 a 2016. Se analizaron resultados mediante Stata 13. Aprobado por Comité de ética del Servicio de Salud Metropolitano Norte RESULTADOS: Se estudian 94 pacientes hospitalizados, mediana de edad de 7,3 meses, 45 (48%) hombres. Los casos de cardiopatía congénita cianótica fueron 7 (7,4%), obstructivas izquierdas 3 (3,2%) y no obstructivas 84 (89,3%). Las comorbilidades fueron: 17 (18,08%) trisomía 21, 10 (10,6%) patología neurológica, 6 (6,38%) reflujo gastroesofágico. Sin comorbilidad 48 pacientes (51,06%). La mediana de hospitalización es 8 días y la necesidad de ventilación mecánica de 1 día, siendo mayor en las cianóticas. Requieren ingreso a unidad de paciente crítico 49 (52,12%). La letalidad fue de un 8,5%. CONCLUSIÓN: La morbimortalidad de la infección por VRS observada en pacientes con cardiópatas congénitas es elevada, por lo que la prevención con anticuerpos monoclonales podría tener impacto. En el 2019 Chile implementa el uso de anticuerpos monoclonales anti VRS en niños con cardiopatías congénitas por lo que será interesante medir el impacto de esta medida.


INTRODUCTION. Congenital heart disease is a risk factor for developing severe disease due to respiratory syncytial virus (RSV). In Chile the rate of hospitalization or lethality due to this cause is not known. The objective of this study was to determine lethality of infants with congenital heart disease hospitalized for RSV infection. METHOD. Retrospective descriptive study, through review of clinical records of infants under 24 months with congenital heart disease, hospitalized due to low RSV respiratory infection. We recorded age, gender, type of congenital heart disease, comorbidities, days of hospitalization, admission to a critical patient unit and lethality in Roberto del Río Hospital between 2014 to 2016. The research had approved bay the ethical Comitee Servicio de Salud Metropolitano Norte. Results were analyzed through Stata 13. RESULTS. 94 hospitalized patients were studied, median age of 7.3 months, 45 (48%) men. The cases of congenital cyanotic heart disease were 7 (7.4%), left obstructive 3 (3.2%) and non-obstructive 84 (89.3%). The comorbidities were: 17 (18.08%) trisomy 21, 10 (10.6%) neurological pathology, 6 (6.38%) gastroesophageal reflux and 48 patients (51.06%) did not present. The hospitalization median is 8 days and the need for 1-day mechanical ventilation is greater in cyanotic patients. They require admission to the critical patient unit 49 (52.12%). The lethality is 8.5%. CONCLUSION: The lethality of RSV infection observed in patients with congenital heart disease is high. In 2019 Chile implemented the use of RSV monoclonal antibodies congenital heart disease. New studies are needed to measure the impact of this new policy. Keywords: congenital heart disease, respiratory syncytial virus


Subject(s)
Humans , Male , Female , Infant, Newborn , Infant , Respiratory Syncytial Virus Infections/mortality , Heart Defects, Congenital/mortality , Oxygen Inhalation Therapy , Respiration, Artificial , Retrospective Studies , Respiratory Syncytial Virus Infections/complications , Respiratory Syncytial Virus Infections/therapy , Heart Defects, Congenital/complications , Hospitalization/statistics & numerical data , Hospitals, Pediatric/statistics & numerical data , Antibodies, Monoclonal/therapeutic use
10.
Rev. colomb. nefrol. (En línea) ; 7(supl.2): 280-284, jul.-dic. 2020. graf
Article in Spanish | LILACS, COLNAL | ID: biblio-1251591

ABSTRACT

Resumen Introducción: el SARS-COV-2 es un nuevo virus que ha traído nuevos retos a los sistemas de salud a nivel mundial y que ha generado controversia en la continuidad en el uso de bloqueadores del receptor de angiotensina por su correlación fisiopatológica con el SARS-COV-2. Objetivo: presentar la evidencia disponible y las actuales recomendaciones sobre el uso de receptores de la enzima convertidora de angiotensina en el tratamiento para COVID-19. Materiales y métodos: se realizó una búsqueda narrativa en la base de datos PubMed sobre artículos que hablaran acerca del receptor de la enzima convertidora de angiotensina asociado a la pandemia actual por COVID-19. El límite de publicación fue el 13 de abril de 2020 y se incluyeron artículos en todos los idiomas. Resultados: se encontraron 14 artículos con contenido científico significativo para el objetivo de la presente revisión. Conclusión: la fisiopatología del SARS-COV-2 aún es desconocida, así como la efectividad de diferentes fármacos de uso cotidiano para su tratamiento. Dentro de los diferentes medicamentos que se han probado para detener el contagio y sus efectos están aquellos con efecto sobre el receptor de la enzima convertidora de angiotensina.


Abstract Introduction: As a new disease, SARS-COV-2 is a new challenge for healthcare system worldwide, with physiopathology under study and controversy about Angiotensin Converting Enzyme Blockers use because of It's physiopatological correlation with SARS-Cov-2. Objetive: Search for novel literature and recent recomendations about use of Angiotensin Converting Enzyme Blockers during Covid-19 illness. Materials and Methods: We look for narrative literature at PubMed Database for articles about Angiotensin Converting Enzyme and Covid-19 pandemic. Searching limit was April 13 of2.020, we included all languages. Results. We included 14 articles with significative scientific content for review objetive. Conclusion: SARS-Cov-2 Physiopatology is still unclear, also, pharmacology effectiveness in it's treatment. One of these pharmacology groups are the Angiotensin Converting Enzyme Blockers with uncertainty about it's safety during COVID-19 illness.


Subject(s)
Humans , Male , Female , Peptidyl-Dipeptidase A , COVID-19 , Respiratory Distress Syndrome, Newborn , Receptors, Angiotensin , Colombia , Severe acute respiratory syndrome-related coronavirus
11.
Acta méd. costarric ; 62(4)dic. 2020.
Article in Spanish | LILACS, SaludCR | ID: biblio-1383343

ABSTRACT

Resumen Antecedentes: La bronquiolitis es la infección del tracto respiratorio inferior más frecuente en lactantes. El virus respiratorio sincicial es el principal agente y responde hasta por un 85 % de los casos. Los principales factores de riesgo asociados son: sexo masculino; lactantes menores; prematuros; patologías médicas de fondo como: cardiopatía congénita, displasia broncopulmonar, síndrome de Down y enfermedades neuromusculares; así como otros factores ambientales y sociales. El objetivo de este estudio fue caracterizar los prematuros, el tratamiento utilizado, el perfil de la inmunofluorescencia viral, las complicaciones, el uso de palivizumab y los costos de hospitalización en pacientes hospitalizados por bronquiolitis durante enero de 2011 y diciembre de 2011. Pacientes y métodos: Estudio observacional, descriptivo, basado en la revisión retrospectiva de expedientes clínicos de una serie de pacientes hospitalizados en el Hospital Nacional de Niños de la Caja Costarricense de Seguro Social. Se incluyeron todos los pacientes menores de 2 años egresados con el diagnóstico de bronquiolitis durante 2011, con el antecedente de prematuridad (menor de 37 semanas de edad gestacional). Resultados: Se incluyó un total de 141 pacientes; un 63 % (n=89) de sexo masculino, promedio de edad 5,7 meses (rango 0-24). Un 43 % (n=61) de los pacientes manifestó bronquiolitis antes de los 3 meses de edad. Con respecto a la edad gestacional, se obtuvo que el 35,46 % de los pacientes eran de 32 a 35 semanas, de 35 a 37 semanas un 31,2 %, de 30 a 32 semanas un 19,86 % y el resto menores de las 29 semanas. En 93 niños (66 %) se anotó el antecedente de tabaquismo en el entorno del hogar; de forma específica, en 17 % de estos pacientes se presentó el antecedente de tabaquismo pasivo, al reportarse que el padre o el abuelo eran los fumadores activos. El antecedente heredofamiliar de asma fue positivo en el 41,8 %. Con respecto al tratamiento recibido durante su hospitalización, el 100 % ameritó oxígeno suplementario y un 61 % recibió nebulizaciones con salbutamol; los esteroides sistémicos se utilizaron en el 33 % de los pacientes y solo en un 29 % se utilizó la terapia antibiótica. Un 28 % de la población estudiada presentó complicaciones, de los cuales 28 (19,86 %) prematuros ameritaron soporte ventilatorio. El hallazgo de atelectasia en la radiografía de tórax se evidenció en el 7,8 % de los pacientes. Únicamente un 4,25 % de los pacientes tuvo una sobreinfección bacteriana. Debido a la dificultad de los accesos venosos de este grupo de niños, 14 (9,93 %) ameritaron la colocación de catéter venoso central. El rango de estancia hospitalaria fue de 1 a 31 días, con un promedio de 7; la hospitalización en la Unidad de Cuidados Intensivos alcanzó un rango de 5 a 18 días, con un promedio de 10, y el promedio de la necesidad de ventilación mecánica asistida fue de 8,2 días, y de cánula de alto flujo de 2,8 días. Únicamente un 6,38 % (n=9) tenía el antecedente de haber recibido profilaxis con palivizumab: la mayoría había recibido más de dos dosis y ninguno de los pacientes había completado el esquema de las 5 dosis. Durante 2011, el Hospital reportó que el costo promedio diario fue de ¢ 766 476. Con un total de 1001 días de hospitalización acumulada, se estimó un costo directo de ¢ 767 242 142, equivalente a $ 1 522 306 (dólares estadounidenses). Conclusión: El perfil de los prematuros en este estudio es muy similar a lo reportado internacionalmente, por ser un grupo de prematuros con prevalencia más elevada de complicaciones que la población pediátrica general. Dado el costo que implica el internamiento de estos pacientes, es necesario evaluar la aplicación de intervenciones como el palivizumab para prevenir la hospitalización y disminuir otros costos al sistema de salud solidario.


Abstract Background: Bronchiolitis is the most common lower respiratory tract infection in infants. Respiratory Syncytial Virus is the main agent and responds in up to 85% of cases. The main associated risk factors are: male sex, young infants, premature infants, underlying medical conditions such as: congenital heart disease, bronchopulmonary dysplasia, Down syndrome and neuromuscular diseases; as well as other environmental and social factors. The objective of this study was to characterize preterm infants, the treatment used, the viral immunofluorescence profile, complications, the use of palivizumab, and hospitalization costs in patients hospitalized for bronchiolitis during January 2011 and December 2011. Methods: An observational, descriptive study, based on a retrospective review of clinical records of a series of hospitalized patients at the National Children's Hospital (HNN) of the Costa Rican Social Security Fund. All patients under 2 years of age who were discharged with a diagnosis of bronchiolitis during 2011, with a history of prematurity (less than 37 weeks gestational age) were included. Results: A total of 141 patients were included, 63% (n = 89) were male, with an average age of 5.7 months (range 0-24). 43% (n = 61) of patients with Bronchiolitis manifested before 3 months of age. With regard to gestational age, it was found that 35.46% of the patients were between 32 and 35 weeks, 31.2% from 35 to 37 weeks, 19.86% from 30 to 32 weeks and the rest were under 29 weeks. In 93 children (66%) a history of smoking was noted in the home environment; specifically, 17% of these patients had a history of passive smoking as the father or grandfather was reported as active smokers. In relation to the hereditary family history of asthma, it was positive in 41.8%. Regarding the treatment received during their hospitalization, 100% required supplemental oxygen and 61% received nebulizations with salbutamol; systemic steroids were used in 33% of patients and antibiotic therapy was used in only 29%. 28% of the population studied presented complications, of which 28 (19.86%) premature babies required ventilatory support. The finding of atelectasis on the chest X-ray occurred in 7.8% of the patients. Only 4.25% of the patients had a bacterial superinfection. Due to the difficulty of the venous access in this group of children, 14 (9.93%) of them required the placement of a central venous catheter. The range of hospital stay was from 1 to 31 days with an average of 7 days, hospitalization in the Intensive Care Unit reached a range of 5 to 18 days with an average of 10 days and the average need for assisted mechanical ventilation It was 8.2 days and the high-flow cannula was 2.8 days. Only 6.38% (n = 9) had a history of having received prophylaxis with Palivizumab, the majority had received more than two doses, and none of the patients had completed the 5-dose schedule. During that year 2011, the hospital reported that the average daily cost was ¢ 766 476; With a total of 1001 cumulative hospitalization days, a total direct cost of ¢ 767 242 142 was estimated, equivalent to $ 1 522 306 (US dollars). Conclusion: The profile of the characteristics of premature infants in this study is very similar to that reported internationally, as it is a group of premature infants with a higher prevalence of complications than the general pediatric population. Given the cost involved in the hospitalization of these patients, it is necessary to evaluate the application of interventions such as palivizumab to prevent hospitalization and reduce other costs to the solidarity health system.


Subject(s)
Humans , Infant, Newborn , Bronchiolitis/diagnosis , Bronchiolitis/economics , Infant, Premature
12.
Rev. argent. microbiol ; 52(4): 111-120, dic. 2020. graf
Article in English | LILACS | ID: biblio-1340926

ABSTRACT

Abstract Bovine respiratory syncytial virus (BRSV) is one of the most relevant agents responsi-ble for respiratory disease in cattle from both dairy and beef farms. BRSV is spread by horizontalcontact causing a constant presence of seropositive animals that favors viral circulation throughout the year. Moreover, reinfections with BRSV are frequent between animals regardless of theirage as BRSV does not confer long-lasting protective immunity. Several studies have demonstrated the circulation of BRSV in cattle from different regions of the world; however, little isknown about the dynamics of BRSV infection in cows before and after they begin lactation. Theaim of this work was to study the dynamics of BRSV neutralizing antibodies from birth up to36 months of age in a closed dairy herd of Argentina specifically around the lactation period. Passive maternal antibodies against BRSV started to decrease monthly and became almost undetectable at 8 months of age. We detected two potential infection points at months 11 and 27after birth, in which 30% and 45% of the animals showed seroconversion, respectively. Specifically, an increase in the proportion of seropositive cows after the start of lactation suggests thatthey became reinfected around the time they began lactating. We demonstrate the importanceof understanding BRSV dynamics in a closed dairy herd to review the vaccination schedule ofthe animals to achieve protection against BRSV infection.


Resumen El virus respiratorio sincitial bovino (Bovine respiratory syncytial virus, [BRSV]) es uno de los principales agentes responsables de la enfermedad respiratoria en bovinos, tanto de tambos como de cría. El virus se transmite horizontalmente y causa la presencia constante de animales seropositivos, lo cual favorece la circulación viral a lo largo del ano. A su vez, las reinfecciones por BRSV son frecuentes entre animales independientemente de su edad, dado que el virus no confiere inmunidad protectora a largo plazo. Numerosos estudios han demostrado la circulación de BRSV en bovinos de diferentes regiones del mundo, sin embargo, poco se conoce acerca de la dinámica de infección en vacas antes y después del inicio de la fase de lactancia. El objetivo de este trabajo fue estudiar la dinámica de anticuerpos neutralizantes anti- BRSV en vacas lecheras desde el nacimiento hasta los 36 meses de vida en un tambo cerrado de Argentina, específicamente, en el período de lactancia. Los anticuerpos pasivos específicos para BRSV comenzaron a declinar mensualmente hasta ser casi indetectables a los 6 meses. Detectamos dos potenciales puntos de infección a los meses 11 y 27 luego del nacimiento, momentos en los que el 30 y el 45% de los animales mostraron seroconversión, respectivamente. El incremento en la proporción de vacas seropositivas luego del comienzo de la lactancia sugiere que estas se reinfectaron en el inicio de dicha etapa. Demostramos la importancia de entender la dinámica de circulación del BRSV en un tambo cerrado, a fin de revisar el esquema de vacunación de los animales para que estén protegidos frente a la posible infección por este virus.


Subject(s)
Animals , Cattle , Respiratory Syncytial Virus, Bovine , Antibodies, Neutralizing , Argentina , Cattle Diseases/virology , Respiratory Syncytial Virus, Bovine/immunology
13.
Rev. Méd. Clín. Condes ; 31(3/4): 343-351, mayo.-ago. 2020. tab
Article in Spanish | LILACS | ID: biblio-1223773

ABSTRACT

La vacunación es el medio más efectivo para controlar la morbilidad y mortalidad relacionadas con enfermedades infecciosas. Para lograr esto, necesitamos vacunas inmunogénicas y seguras que faciliten y mejoren sus condiciones de transporte, almacenamiento y administración. Gracias a los avances en inmunología y bioinformática, es posible impulsar el descubrimiento de nuevas vacunas para enfrentar la tuberculosis, el virus respiratorio sincicial, el Streptococcus agalactiae, la enfermedad meningocócica invasora, entre otros. Así también, nuevas tecnologías, como la producción de vacunas utilizando plantas transgénicas y parches de microagujas, los cuales podrían facilitar la producción, disminuir los costos y efectos adversos. Sin embargo, no solo necesitamos las vacunas, sino que debemos conocer la epidemiología de las enfermedades prevenibles con vacuna para tomar decisiones fundadas, con el objetivo de planificar estrategias sanitarias, medir su impacto y evaluar la seguridad de su utilización, para alcanzar las metas de salud pública y la confianza de la población.


Vaccination is the most effective strategy to avoid morbidity and mortality related to infectious diseases. To achieve this, we need immunogenic and safe vaccines that facilitate and improve its transport, storage and administration conditions. Thanks to current advances in immunology and bioinformatics, it is possible to boost the discovery of new vaccines to deal with tuberculosis, the respiratory syncytial virus, Streptococcus agalactiae, meningococcal invasive disease, among others. In addition to new technologies such as the production of plant-based vaccines, and microneedles patches, which can facilitate its production, reducing costs and adverse effects. However, vaccines is not the only thing that we need, because we must know the epidemiology and burden of disease to take informed decisions to design optimal strategies, measuring their impact and assessing the safety of their use in order to achieve the goals health and population confidence.


Subject(s)
Humans , Vaccines/administration & dosage , Communicable Disease Control/methods , Vaccination/trends , Health Priorities , Streptococcal Infections/prevention & control , Adjuvants, Immunologic , Immunization/trends , Respiratory Syncytial Virus Infections/prevention & control , Respiratory Syncytial Virus Vaccines/administration & dosage , Tuberculosis Vaccines/administration & dosage , Decision Making , Meningococcal Infections/prevention & control
14.
Rev. chil. pediatr ; 91(2): 216-225, abr. 2020. tab, graf
Article in Spanish | LILACS | ID: biblio-1098894

ABSTRACT

Resumen: Objetivo: describir las terapias utilizadas en lactantes con bronquiolitis aguda admitidos en 20 Uni dades de Cuidados Intensivos (UCI) pediátricos miembros de LARed en 5 países latinoamerica nos. Pacientes y Método: Estudio observacional retrospectivo, multicéntrico, de datos del Registro Latinoamericano de Falla Respiratoria Aguda Pediátrica. Se incluyeron niños menores de 2 años ingresados a UCI pediátrica por bronquiolitis aguda comunitaria entre mayo-septiembre 2017. Se recolectaron datos demográficos, clínicos, soporte respiratorio, terapias utilizadas y resultados clí nicos. Se realizó análisis de subgrupos según ubicación geográfica, tipo financiación y presencia de academia. Resultados: Ingresaron al registro 1155 pacientes con falla respiratoria aguda. Seis casos fueron excluidos por no tener formulario completo. De los 1147 pacientes, 908 eran menores de 2 años. De ellos, 467 tuvieron diagnóstico de bronquiolitis aguda, correspondiendo a la principal causa de ingreso a UCI pediátrica por falla respiratoria aguda (51,4%). Las características demográficas y de gravedad entre los centros fueron similares. El soporte máximo respiratorio más frecuente fue cánula nasal de alto flujo (47%), seguido por ventilación mecánica no invasiva (26%) y ventilación mecánica invasiva (17%), con un coeficiente de variación (CV) amplio entre los centros. Hubo una gran dispersión en uso de terapias, siendo frecuente el uso de broncodilatadores, antibióticos y corticoides, con CV hasta 400%. El análisis de subgrupos mostró diferencias significativas en soporte respiratorio y tratamientos utilizados. Un paciente falleció en esta cohorte. Conclusión: Detectamos gran variabilidad en el soporte respiratorio y tratamientos entre UCI pediátricas latinoamericanas. Esta variabilidad no es explicada por disparidades demográficas ni clínicas. Esta heterogeneidad de tratamientos debería promover iniciativas colaborativas para disminuir la brecha entre la evidencia científica y la práctica asistencial.


Abstract: The objective of this study was to describe the management of infants with acute bronchiolitis admit ted to 20 pediatric intensive care units (PICU) members of LARed in 5 Latin American countries. Pa tients and Method: Retrospective, multicenter, observational study of data from the Latin American Registry of Acute Pediatric Respiratory Failure. We included children under 2 years of age admitted to the PICU due to community-based acute bronchiolitis between May and September 2017. Demo graphic and clinical data, respiratory support, therapies used, and clinical results were collected. A subgroup analysis was carried out according to geographical location (Atlantic v/s Pacific), type of insurance (Public v/s Private), and Academic v/s non-Academic centers. Results: 1,155 patients were included in the registry which present acute respiratory failure and 6 were excluded due to the lack of information in their record form. Out of the 1,147 patients, 908 were under 2 years of age, and out of those, 467 (51.4%) were diagnosed with acute bronchiolitis, which was the main cause of admission to the PICU due to acute respiratory failure. The demographic and severity characteristics among the centers were similar. The most frequent maximum ventilatory support was the high-flow nasal can nula (47%), followed by non-invasive ventilation (26%) and invasive mechanical ventilation (17%), with a wide coefficient of variation (CV) between centers. There was a great dispersion in the use of treatments, where the use of bronchodilators, antibiotics, and corticosteroids, representing a CV up to 400%. There were significant differences in subgroup analysis regarding respiratory support and treatments used. One patient of this cohort passed away. Conclusion: we detected wide variability in respiratory support and treatments among Latin American PICUs. This variability was not explained by demographic or clinical differences. The heterogeneity of treatments should encourage collabora tive initiatives to reduce the gap between scientific evidence and practice.


Subject(s)
Humans , Male , Female , Infant, Newborn , Infant , Practice Patterns, Physicians'/statistics & numerical data , Bronchiolitis/therapy , Intensive Care Units, Pediatric/statistics & numerical data , Guideline Adherence/statistics & numerical data , Critical Care/statistics & numerical data , Healthcare Disparities/statistics & numerical data , Bronchiolitis/diagnosis , Registries , Acute Disease , Retrospective Studies , Practice Guidelines as Topic , Critical Care/methods , Latin America
15.
J. pediatr. (Rio J.) ; 94(5): 554-558, Sept.-Oct. 2018. tab, graf
Article in English | LILACS | ID: biblio-975983

ABSTRACT

Abstract Objective: Characterize the role of human parainfluenza virus and its clinical features in Brazilian children under 2 years of age presenting with acute lower respiratory tract infections. Methods: Real-time assays were used to identify strains of human parainfluenza virus and other common respiratory viruses in nasopharyngeal aspirates. One thousand and two children presenting with acute lower respiratory tract illnesses were enrolled from February 2008 to August 2010. Results: One hundred and four (10.4%) patients were human parainfluenza virus positive, of whom 60 (57.7%) were positive for human parainfluenza virus-3, 30 (28.8%) for human parainfluenza virus-4, 12 (11.5%) for human parainfluenza virus-1, and two (1.9%) for human parainfluenza virus-2. Seven (6.7%) patients had more than one strain of human parainfluenza virus detected. The most frequent symptoms were tachypnea and cough, similar to other viral respiratory infections. Clinical manifestations did not differ significantly between human parainfluenza virus-1, -2, -3, and -4 infections. Human parainfluenza virus-1, -3, and -4 were present in the population studied throughout the three years of surveillance, with human parainfluenza virus-3 being the predominant type identified in the first two years. Conclusion: Human parainfluenza viruses contribute substantially to pediatric acute respiratory illness (ARI) in Brazil, with nearly 30% of this contribution attributable to human parainfluenza virus-4.


Resumo Objetivo: Caracterizar o papel do VPH-4 e suas características clínicas em crianças brasileiras com menos de dois anos de idade com infecções agudas do trato respiratório inferior. Métodos: Ensaios em tempo real foram utilizados para identificar tipos de VPH e outros vírus respiratórios comuns em aspirados nasofaríngeos. Mil e duas crianças com doença aguda do trato respiratório inferior foram inscritas para participar de fevereiro de 2008 a agosto de 2010. Resultados: 104 (10,4%) pacientes eram VPH positivos, dos quais 60 (57,7%) eram positivos para VPH-3, 30 (28,8%) para VPH-4, 12 (11,5%) para VPH-1 e dois (1,9%) para VPH-2. Sete (6,7%) pacientes apresentaram mais de um tipo de VPH detectado. Os sintomas mais frequentes foram tosse e taquipneia, semelhantes a outras infecções respiratórias virais. As manifestações clínicas não diferiram de forma significativa entre as infecções por VPH-1, -2, -3 e -4. Os VPH-1, -3 e -4 estavam presentes na população estudada ao longo dos três anos de vigilância, e o VPH-3 foi o tipo predominante identificado nos primeiros dois anos. Conclusão: Os VPHs contribuem substancialmente para a DRA pediátrica no Brasil com quase 30% dessa contribuição atribuível ao VPH-4.


Subject(s)
Humans , Infant, Newborn , Infant , Child, Preschool , Respiratory Tract Infections/virology , Parainfluenza Virus 4, Human/genetics , Seasons , Nasopharynx/virology , Population Surveillance , Acute Disease , Reverse Transcriptase Polymerase Chain Reaction , Parainfluenza Virus 4, Human/isolation & purification , Real-Time Polymerase Chain Reaction
16.
Rev. chil. pediatr ; 89(4): 462-470, ago. 2018. tab, graf
Article in Spanish | LILACS | ID: biblio-959547

ABSTRACT

INTRODUCCIÓN: Dada la alta prevalencia de infecciones respiratorias en lactantes hospitalizados por Virus Respiratorio Sincicial (VRS), el objetivo de este estudio apuntó a determinar los costos directos de esta infección. PACIENTES Y MÉTODO: Estudio prospectivo longitudinal en lactantes menores de un año hospitalizados por VRS durante el año 2015. Los pacientes se dividieron en 2 grupos. Grupo 1 sin factores de riesgo y grupo 2 con factores de riesgo (prematurez, oxigeno dependencia, displasia broncopulmonar, cardiopatía, inmunodeficiencia), comparando entre sí el estado nutricional, género, lactancia materna, diagnóstico de egreso, diagnóstico radiológico, tiempo de estadía, entre otras. Se estimó costos directos por hospitalización según aranceles del Fondo Nacional de Salud (FONASA) y Modalidad Atención Institucional (MAI). RESULTADOS: Ingresaron 260 pacientes distribuidos, 234 en grupo 1 (90%) y 26 en grupo 2 (10%). El promedio de estadía hospitalaria fue 7,3 días (DS+5,1) para grupo 1 y 13,6 días (DS+16,3) grupo 2 (p < 0,05), con medianas de 6 y 7 días, respectivamente. El costo directo asociado a hospitalización por VRS fue en promedio CLP $ 413.529 (632,1 US$) para grupo 1 y de CLP $ 744.260 (1.137,6 US$) para grupo 2 (p < 0,05).También hubo significancia estadística por mayor costo en grupo 2 para el rubro exámenes y medicamentos (p < 0,03) y costos por días de estadía hospitalaria (p < 0,05). CONCLUSIÓN: Estos valores por primera vez conocidos en la realidad nacional, confirman el alto costo de estas infecciones y, en particular, en pacientes perte necientes a grupos de riesgo.


INTRODUCTION: Considering the high prevalence of respiratory infections in hospitalized infants with Respiratory Syncytial Virus (RSV), the objective of this study is to determine the direct costs of this infection. PATIENTS Y METHOD: Method: Prospective longitudinal study in infants under one year of age hos pitalized due to RSV during 2015. The patients were divided into 2 groups, Group 1 patients without risk factors and Group 2 patients with risk factors (prematurity, oxygen dependence, bronchopulmo nary dysplasia, heart disease, immunocompromised patients), comparing each other variables such as nutritional status, gender, breastfeeding, discharge diagnosis, radiological diagnosis, length of hos pital stay, among others. Direct costs for hospitalization were estimated according to the fees of the National Health Fund (FONASA) and the Modality of Institutional Care (MAI). RESULTS: The total patients admitted in the period were 260: 234 (90%) in Group 1 and 26 (10%) in Group 2. The avera ge hospital stay for Group 1 was 7.3 days (SD+5.1) with a median of 6 days, and 13.6 days (SD+16.3) for Group 2 with a median of 7 days (p < 0.05). The direct costs associated with RSV hospitalization were on average CLP $ 413,529 (US$ 632.1) for Group 1, and CLP $ 744,260 (US$ 1,137.6) for Group 2 (p < 0.05). There was also statistically significant higher cost for Group 2 due to tests and drugs (p < 0.05) and costs per day of hospital stay (p < 0.05). CONCLUSION: These values, known for the first time in the national reality, confirm the high cost of these infections and particularly in risk groups.


Subject(s)
Humans , Male , Female , Infant, Newborn , Infant , Respiratory Syncytial Virus Infections/economics , Hospital Costs/statistics & numerical data , Hospitalization/economics , Chile , Prospective Studies , Longitudinal Studies , Respiratory Syncytial Virus Infections/therapy
17.
Pesqui. vet. bras ; 38(4): 642-648, abr. 2018. tab
Article in English | LILACS, VETINDEX | ID: biblio-955389

ABSTRACT

Bovine respiratory disease (BRD) is responsible for economic losses in cattle production. Viruses are categorized as primary etiological agents. The aims of this study were to evaluate the presence of antibodies against bovine viral diarrhea virus (BVDV), bovine herpes virus type 1 (BoHV-1), and bovine respiratory syncytial virus (BRSV) in healthy and BRD calves from family farming in relation to clinical signs of BRD. Hundred and forty-five calves were randomly selected and physical examination was performed. Only 123 animals were classified as healthy and BRD calves. Antibodies were evaluated by virus neutralization test. Person's Chi-square test and Fisher's exact test were performed as univariate analysis. Binary Logistic Regression was applied as multivariate analysis. Variables with P<0.10 were considered statistically significant. Variables with 0.15<P<0.10 were considered as statistical tendencies. Antibodies against BoHV-1, BVDV, and BRSV were detected in 32%, 23% and 37% animals. Antibodies against both three viruses were detected in 26.8% of calves. The presence of antibodies against BRSV were associated to normal heart rates (P=0.018) and unilateral airflow (P=0.035). Tendency was observed to unilateral airflow (P=0.06) Statistical tendencies were observed to Ab-BoHV-1 and body temperature (P=0.119) and breathing pattern (P=0.123). The profile of antibodies against respiratory viruses in calves from Brazilian family farming was firstly described. The results confirmed the importance of some clinical signs to viral infection.(AU)


A doença respiratória dos bovinos (DRB) é responsável por importantes perdas econômicas para a produção bovina, com maior impacto na agricultura familiar. Os vírus são comumente caracterizados como agentes etiológicos primários devido a mudanças na mucosa respiratória, na produção de citocinas e no funcionamento do sistema imune. Os objetivos deste estudo transversal foram avaliar a presença de anticorpos contra o vírus da diarreia viral bovina (VDVB), herpes vírus bovino tipo 1 (HVbo-1) e vírus respiratório sincicial bovino (VRSB) em bezerros sadios e com DRB de assentamentos em associação com a presença sinais clínicos de DRB. Cento e quarenta e cinco animais foram randomicamente selecionados e exame físico foi realizado. Somente 123 animais foram classificados em sadios e com DRB. Anticorpos foram identificados pelo teste de virusneutralização. Teste de qui-quadrado e teste exato de Fisher foram utilizados como análise univariada. A análise multivariada foi realizada pela regressão binária logística com o método Backward conditional. Variáveis com P<0,10 foram considerados significantes. Variáveis com 0,15<P<0,10 foram consideradas tendências. Anticorpos contra HVbo-1, VDVB e VRSB foram detectados em 32%, 23% e 37% dos animais. A presença concomitante de anticorpos contra os três vírus foi detectada em 26,8% dos bezerros. A presença de anticorpos contra VRSB foi associada à frequência cardíaca normal (P=0,018) e fluxo de ar nasal unilateral (P=0,035). Tendência estatística observada para anticorpos contra VDVB temperatura corporal (P=0,119) e padrão respiratório (P=0,123). Ao nosso conhecimento, este é o primeiro estudo que objetivou a avaliação da presença de anticorpos contra VDVB, VRSB e HVbo-1 em bezerros de assentamentos do estado de São Paulo, Brasil e sua relação com as manifestações clínicas da DRB.(AU)


Subject(s)
Animals , Cattle , Cattle/physiology , Serologic Tests/veterinary , Bovine Respiratory Disease Complex/pathology
18.
Arq. bras. med. vet. zootec. (Online) ; 70(5): 1414-1422, set.-out. 2018. graf
Article in Portuguese | LILACS, VETINDEX | ID: biblio-946869

ABSTRACT

Esta pesquisa avaliou a TIP e a dinâmica de anticorpos (ACs) específicos em bezerros naturalmente expostos aos agentes causadores da doença respiratória bovina (DRB). Foram selecionados 19 bezerros Holandeses alimentados com colostro proveniente de doadoras vacinadas para DRB. Amostras de soro foram obtidas antes e após a ingestão do colostro (48h) para a soroneutralização (SN). Os valores médios (log2) detectados após colostragem foram de 11,5±1,6 (BVDV), 8,8±1,3 (BoHV-1), 5,5±1,6 (BRSV) e 8,4±1,5 (BPIV-3). Cinco bezerros foram criados do nascimento aos 240 dias de vida, observando-se decréscimo nos títulos de ACs para BVDV, BoHV-1 e BPIV-3 ao longo do tempo (P≤0,001). As taxas de infecções detectadas entre o D14 e o D240 foram de 40% (2/5), 20% (1/5), 80% (4/5), e 60% (3/5), respectivamente, para BVDV, BoHV-1, BRSV e BPIV-3. A maioria dos bezerros manifestou broncopneumonia após as infecções virais. Os bezerros apresentaram ACs para todas as viroses às 48 horas de vida, porém os títulos adquiridos para o BRSV foram baixos. A susceptibilidade para as infecções variou de acordo com os níveis e a duração dos títulos de ACs maternos.(AU)


This research evaluated the PIT and the dynamics of specific antibody (Ab) for calves naturally exposed to the viral agents involved in Bovine Respiratory Disease (BRD). Nineteen Holstein calves fed colostrum from vaccinated donors for DRB. Serum samples were obtained before and after colostrum intake (48h) for serum neutralization (SN). Mean values (log2) detected after colostrum feeding were 11.5±1.6 (BVDV), 8.8 ±1.3 (BoHV-1) 5.5±1.6 (BRSV) and 8.4±1.5 (BPIV-3). Five calves were raised from birth to 240 days of life and presented a decrease in Ab titers for BVDV, BoHV-1 and BPIV-3 over time (P≤ 0.001). Infection rates from D14 to D240 were of 40% (2/5), 20% (1/5), 80% (4/5) and 60% (3/5), respectively for BVDV, BoHV-1, BRSV and BPIV-3. Most of the calves presented bronchopneumonia after seroconversion to the virus. Calves presented Ab for all viruses at 48 hours of life, however BRSV Ab titer were low. Levels and persistence of maternal antibody titers determined the susceptibility to viral infections.(AU)


Subject(s)
Animals , Cattle , Cattle/immunology , Immunization, Passive/veterinary , Virus Diseases/immunology , Herpesvirus 1, Bovine
19.
Rev. chil. enferm. respir ; 33(4): 293-302, dic. 2017. tab, graf
Article in Spanish | LILACS | ID: biblio-1042618

ABSTRACT

Desde el descubrimiento del virus respiratorio sincicial (VRS) en 1956, se ha demostrado en todo el mundo su impacto como el principal causante de infecciones respiratorias agudas bajas (IRAB) que requieren hospitalización en el lactante. Posteriormente se ha descrito que una inadecuada respuesta inmune favorece reinfecciones en la infancia. Más recientemente, numerosos trabajos epidemiológicos lo han asociado a IRAB en adultos, especialmente de tercera edad y en ciertos pacientes inmunocomprometidos. Se ha avanzado en el conocimiento de la estructura y función de los diferentes componentes del VRS, lo que ha permitido facilitar su diagnóstico y avanzar en estrategias de desarrollo de antivirales y vacunas. En efecto, el diagnóstico de laboratorio de VRS es muy simple en niños, por su alta excreción viral, pero para demostrar su participación en adultos se requieren técnicas de alta sensibilidad. La patogenia de la infección es muy compleja y muchos aspectos todavía no se han aclarado. Intervienen factores dependientes del virus -cepa, dosis infectiva, capacidad del virus de inhibir la respuesta inmune- y del hospedero humano, como edad, enfermedades concomitantes, integridad del aparato inmune y otros. Se menciona que otros factores como frío, humedad ambiental, contaminación aérea, hacinamiento, también actuarían en combinación con los inicialmente mencionados. Es necesario conocer los mecanismos responsables de la adquisición de inmunidad contra el VRS para entender las estrategias usadas en el intento de desarrollar vacunas, cuyos esfuerzos son todavía infructuosos. Actualmente se conoce bastante del VRS como patógeno de niños. Sin embargo, cada día se documenta más su participación en enfermedades de adultos, por lo que haremos un resumen para promover su consideración como posible patógeno respiratorio.


Since respiratory syncytial virus (RSV) was identified in 1956, its impact as the main cause of severe acute lower respiratory infections in infants has been shown. Studies about RSV immunopathogenesis have demonstrated that the host immune response is important in protecting from re-infections. The presence of RSV in exacerbation of chronic diseases as COPD and bronchial asthma in adults and its severity in cases with immunodeficiency has been also related to an inadequate response. The actual knowledge on the molecular structure and functions of the virus has allowed to improve diagnosis and to develop new strategies for vaccines and antiviral drugs. The etiologic diagnosis in children is easier than in adults due to the higher viral shedding; therefore techniques based on antibody reactions (immunofluorescence, immunocromatography, etc) are good enough in this group. By contrast, in adults, highly sensitive molecular techniques are needed. Although the advances in understanding the pathogenesis process in neonates and infants, many pathogenic factors still need to be elucidated. The virus strains, viral loads and immune response have been described as important players; however, the changes on the host immunity to RSV according to age and co-morbidities associated to severity of illness needs to be explored. RSV has been known as a children pathogen, nowadays this agent is being recognized as an important agent in adults, especially in those with chronic diseases, immunodeficiency and in immune-senescence.


Subject(s)
Humans , Child , Adult , Respiratory Syncytial Viruses/pathogenicity , Respiratory Syncytial Virus Infections/virology , Respiratory Syncytial Viruses/immunology , Viral Vaccines , Respiratory Syncytial Virus Infections/diagnosis , Respiratory Syncytial Virus Infections/immunology , Respiratory Syncytial Virus Infections/therapy
20.
J. pediatr. (Rio J.) ; 93(3): 294-300, May.-June 2017. tab, graf
Article in English | LILACS | ID: biblio-841355

ABSTRACT

Abstract Objectives: To report epidemiological features, clinical characteristics, and outcomes of human rhinovirus (HRV) infections in comparison with other community acquired respiratory virus (CRV) infections in patients hospitalized for two consecutive years. Methods: This was a cross-sectional study. Clinical, epidemiological, and laboratory data of patients hospitalized with acute respiratory syndrome in a tertiary care hospital from 2012 to 2013 were reviewed. Results: HRV was the most common CRV observed (36%, 162/444) and was present in the majority of viral co-detections (69%, 88/128), mainly in association with human enterovirus (45%). Most HRV-infected patients were younger than 2 years (57%). Overall, patients infected with HRV had a lower frequency of severe acute respiratory infection than those infected with other CRVs (60% and 84%, respectively, p = 0.006), but had more comorbidities (40% and 27%, respectively; p = 0.043). However, in the adjusted analysis this association was not significant. The mortality rate within the HRV group was 3%. Detection of HRV was more prevalent during autumn and winter, with a moderately negative correlation between viral infection frequency and temperature (r = −0.636, p < 0.001) but no correlation with rainfall (r = −0.036, p = 0.866). Conclusion: HRV is usually detected in hospitalized children with respiratory infections and is often present in viral co-detections. Comorbidities are closely associated with HRV infections. These infections show seasonal variation, with predominance during colder seasons.


Resumo Objetivos: Relatar as características epidemiológicas, as características clínicas e os resultados das infecções por rinovírus humano (RVH) em comparação a outras infecções por vírus respiratórios adquiridos na comunidade (VRCs) em pacientes internados por dois anos consecutivos. Métodos: Este foi um estudo transversal. Foram revisados os dados clínicos, epidemiológicos e laboratoriais de pacientes internados com síndrome respiratória aguda em um hospital terciário de 2012 a 2013. Resultados: O RVH foi o VRC mais comum observado (36%, 162/444) e esteve presente na maior parte das codetecções virais (69%, 88/128), principalmente em associação ao enterovírus humano (45%). A maioria dos pacientes infectados por RVH possuía menos de 2 anos (57%). De modo geral, os pacientes com RVH apresentaram uma menor frequência de infecção respiratória aguda grave que os pacientes infectados por outros VRCs (60% e 84%, respectivamente, p = 0,006), porém mais comorbidades (40% e 27%, respectivamente; p = 0,043). Contudo, em uma análise ajustada, essa associação não foi significativa. A taxa de mortalidade no grupo RVH foi 3%. A detecção de RVH foi mais prevalente durante o outono e inverno, com uma correlação negativa moderada entre a frequência de infecção viral e a temperatura (r = -0,636, p < 0,001), porém nenhuma correlação com a precipitação (r = −0,036, p = 0,866). Conclusão: O RVH é normalmente detectado em crianças internadas com infecções respiratórias e normalmente está presente em codetecções virais. As comorbidades estão estreitamente associadas a infecções por RVH. Essas infecçõesmostram variação sazonal, com predominância durante as estações mais frias.


Subject(s)
Humans , Male , Female , Child, Preschool , Child , Adolescent , Adult , Middle Aged , Young Adult , Respiratory Tract Infections/epidemiology , Rhinovirus/isolation & purification , Picornaviridae Infections/epidemiology , Respiratory Tract Infections/diagnosis , Respiratory Tract Infections/virology , Rhinovirus/classification , Seasons , Brazil/epidemiology , Prevalence , Cross-Sectional Studies , Picornaviridae Infections/diagnosis , Picornaviridae Infections/virology , Hospitalization
SELECTION OF CITATIONS
SEARCH DETAIL